Honglong Wei
Impact in
- Cell Biology top 10%
- Hippo pathway signaling and YAP/TAZ
- Hepatology top 10%
- Hepatocellular Carcinoma Treatment and Prognosis
Papers in
-
- Protease and Inhibitor Mechanisms 2
- Cancer-related molecular mechanisms research 1
-
- Angiogenesis and VEGF in Cancer 2
- Ubiquitin and proteasome pathways 1
- Co-authors
- Jingtao Zhong (8 shared papers)Peng Xiu (8 shared papers)Fuhai Wang (8 shared papers)Jie Li (8 shared papers)Xueying Sun (4 shared papers)Yong Wang (1 shared paper)Tao Li (1 shared paper)Zongzhen Xu (6 shared papers)
- Journals
- Oncology Reports (4 papers)Tumor Biology (1 paper)Journal of Cancer (1 paper)Chemical Engineering Journal (1 paper)Cell Proliferation (1 paper)
- Partner nations
- ChinaNew Zealand
In The Last Decade
Honglong Wei
12 papers receiving 430 citations
Peers
Comparison fields: 5 of 72
- Cell Biology 131
- Hepatology 57
- Cancer Research 89
- Biochemistry 23
- Oncology 69
Countries citing papers authored by Honglong Wei
This map shows the geographic impact of Honglong Wei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Honglong Wei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Honglong Wei more than expected).
Fields of papers citing papers by Honglong Wei
This network shows the impact of papers produced by Honglong Wei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Honglong Wei. The network helps show where Honglong Wei may publish in the future.
Co-authors
The 25 scholars most cited alongside Honglong Wei, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2016 | 177 | |
| 2 | 2021 | 55 | |
| 3 | 2016 | 30 | |
| 4 | 2018 | 28 | |
| 5 | 2021 | 28 | |
| 6 | 2023 | 24 | |
| 7 | 2015 | 22 | |
| 8 | 2014 | 20 | |
| 9 | 2017 | 19 | |
| 10 | 2017 | 16 | |
| 11 | 2015 | 15 | |
| 12 | 2024 | 1 |
About Honglong Wei
Honglong Wei is a scholar working on Cancer Research, Molecular Biology, Oncology, Cell Biology and Pharmacology, having authored 12 papers that have together received 435 indexed citations. Recurring topics across this work include Hippo pathway signaling and YAP/TAZ (2 papers), Angiogenesis and VEGF in Cancer (2 papers), Inflammatory mediators and NSAID effects (2 papers), Protease and Inhibitor Mechanisms (2 papers), Cancer Mechanisms and Therapy (1 paper), Cancer-related molecular mechanisms research (1 paper), Cholangiocarcinoma and Gallbladder Cancer Studies (1 paper) and Ubiquitin and proteasome pathways (1 paper). The work is most often cited by research in Cell Biology (131 citations), Hepatology (57 citations), Cancer Research (89 citations), Biochemistry (23 citations) and Oncology (69 citations). Honglong Wei has collaborated with scholars based in China and New Zealand. Frequent co-authors include Jingtao Zhong, Peng Xiu, Fuhai Wang, Jie Li, Xueying Sun, Yong Wang, Tao Li, Zongzhen Xu, Feng Liu and Xiaofeng Dong. Their work appears in journals such as Oncology Reports, Tumor Biology, Journal of Cancer, Chemical Engineering Journal and Cell Proliferation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.